R
2.08
0.01 (0.24%)
| Previous Close | 2.07 |
| Open | 2.05 |
| Volume | 292,840 |
| Avg. Volume (3M) | 753,269 |
| Market Cap | 67,061,512 |
| Price / Earnings (Forward) | 59.17 |
| Price / Sales | 0.630 |
| Price / Book | 2.26 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2024 |
| Profit Margin | -5.06% |
| Operating Margin (TTM) | 1.99% |
| Diluted EPS (TTM) | -0.040 |
| Quarterly Revenue Growth (YOY) | 42.90% |
| Total Debt/Equity (MRQ) | 61.18% |
| Current Ratio (MRQ) | 2.00 |
| Operating Cash Flow (TTM) | -4.73 M |
| Levered Free Cash Flow (TTM) | -2.37 M |
| Return on Assets (TTM) | -4.25% |
| Return on Equity (TTM) | -28.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Rockwell Medical, Inc. | Bearish | Bearish |
AIStockmoo Score
0.1
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -4.0 |
| Average | 0.13 |
|
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 12.33% |
| % Held by Institutions | 21.27% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (HC Wainwright & Co., 237.35%) | Buy |
| Median | 6.00 (189.16%) | |
| Low | 5.00 (Rodman & Renshaw, 140.96%) | Buy |
| Average | 6.00 (189.16%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 2.30 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 23 Dec 2024 | 7.00 (237.35%) | Buy | 2.11 |
| 25 Nov 2024 | 7.00 (237.35%) | Buy | 2.31 | |
| Rodman & Renshaw | 14 Nov 2024 | 5.00 (140.96%) | Buy | 2.49 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 17 Dec 2024 | Announcement | Rockwell Medical Enters into a Multi-Year Product Purchase Agreement with the World's Leading Provider of Dialysis Products and Services |
| 12 Dec 2024 | Announcement | Rockwell Medical Promotes Jesse Neri to Chief Financial Officer |
| 05 Dec 2024 | Announcement | Rockwell Medical Partners with HydroCare to Distribute and Install its Dry Acid Concentrate Mix System |
| 19 Nov 2024 | Announcement | Rockwell Medical Expands Distribution in the Philippines |
| 12 Nov 2024 | Announcement | Rockwell Medical Reports Third Quarter 2024 Earnings, Generates Profitability on a Cash Flow and Adjusted EBITDA Basis for the Second Consecutive Quarter |
| 08 Nov 2024 | Announcement | Rockwell Medical Announces Date Change for Third Quarter 2024 Earnings Conference Call and Webcast |
| 14 Oct 2024 | Announcement | Rockwell Medical to Release Third Quarter 2024 Results on Monday, November 11, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |